Search all resources on this page or select a tab to see publications, videos, audio, collections of related resources and more.
Changes to the decision-making process for conditions screened as part of Newborn Bloodspot Screening programs
This fact sheet outlines changes to the decision-making process to add or remove conditions to the Newborn Bloodspot Screening programs.
The National Haemopoietic Progenitor Cell (HPC) Framework aims to guide the effective, evidence-based future operations and management of the Australian HPC sector.
This review considered the future direction of the haemopoietic progenitor cell (HPC) sector. It aims to ensure continued and improved access to therapy for patients with blood or immune disorders, and those receiving chemotherapy or radiation.
The Review of the HPC sector – final report considers the ability for Australia’s haemopoietic progenitor cell (HPC) sector to provide Australians with access to HPCs for transplantation, Australia’s place in the broader international network of HPC providers, and the regulatory context.
Nomination forms for requesting the assessment of a condition for addition to or removal from Newborn Bloodspot Screening
Use these forms to request that a condition be assessed to either be added or removed from the Newborn Bloodspot Screening program.
The BMTP helps patients access international haemopoietic progenitor cell (HPC) donors for transplants. This publication guides people on applying for, participating in and administering the BMTP.
The BMTP helps patients access international haemopoietic progenitor cell (HPC) donors for transplants. Use this form to apply for funding under the BMTP.
This document is a summary of the evidence used to provide a national recommendation on adding congenital adrenal hyperplasia to Australian newborn bloodspot screening programs.
The Newborn Bloodspot Screening National Policy Framework guides the national policies needed to support the ongoing success of newborn bloodspot screening in Australia.